- No file added yet -

Real-world outcomes for patients with metastatic endocrine–responsive breast cancer, with palbociclib-based combinations - supplementary material

figure

posted on 2023-08-02, 08:49 authored by Sarah Sharman Moser, Orr Friedman Mazursky, Hadas Shalev, Lior Apter, Gabriel Chodick, Nava Siegelmann-Danieli

Supplemental Figure 1: Time on treatment by last Palbociclib dose, n=559.

Funding

Pfizer Pharmaceuticals, Israel, (Grant / Award Number:)

History

Usage metrics

Keywords

CDK4/6 inhibitors HR+/HER2- breast cancer observational study palbociclib

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM